gene

MTOR

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MTOR: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

9559Connections

22Hypotheses

15Analyses

50Outgoing

50Incoming

13Experiments

20Debates

Summary

Mechanistic Target of Rapamycin - central kinase regulating autophagy, protein synthesis, and synaptic plasticity in neurodegeneration

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	MTOR
Full Name	Mechanistic Target of Rapamycin
Chromosome	1p36.22
Protein Type	Serine/Threonine Kinase
Target Class	Kinase
Function	mTOR is a central kinase integrating nutritional, growth factor, and energy signals
Mechanism of Action	Prioritized from 1 SciDEX hypotheses, including: APOE-Dependent Autophagy Restoration
Druggability	Low (0.32)
Clinical Stage	Phase I
Molecular Weight	~289 kDa
Amino Acids	2549 amino acids
Pathways	autophagy-lysosome pathway, lysosomal biogenesis
UniProt ID	P42345
NCBI Gene ID	2475
Ensembl ID	ENSG00000164362
OMIM	601231
GeneCards	MTOR
Human Protein Atlas	MTOR
Associated Diseases	AD, ADH, Aging, Als, Alzheimer
Known Drugs/Compounds	alpelisib, Amino Acids, Arsenic trioxide, baicalein, Baicalein, Bnt162B2
Interactions	4EBP1, 6-OHDA, ABCA1, ABCG1, ABCG2, ACAT1
SciDEX Target	View Target Profile (2 clinical trials)
SciDEX Hypotheses	APOE-Dependent Autophagy Restoration Chronic mTORC1-ULK1 signaling blocks autophagy ini Metabolic Checkpoint Reprogramming via TREM2-mTOR (+3 more)
KG Connections	5905 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: MTOR — AlphaFold P42345 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (10)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    subgraph Signaling["Signaling"]
        MTOR["MTOR"] -->|"regulates"| Mtor["Mtor"]
        MTOR["MTOR"] -->|"regulates"| Autophagy["Autophagy"]
        MTOR["MTOR"] -.->|"inhibits"| Als["Als"]
        MTOR["MTOR"] -.->|"inhibits"| Autophagy_1["Autophagy"]
        MTOR["MTOR"] -.->|"inhibits"| Mtor_2["Mtor"]
        MTOR["MTOR"] -->|"activates"| Neurodegeneration["Neurodegeneration"]
        AKT["AKT"] -->|"activates"| MTOR["MTOR"]
        PINK1["PINK1"] -->|"activates"| MTOR["MTOR"]
        LC3["LC3"] -->|"activates"| MTOR["MTOR"]
        ULK1["ULK1"] -->|"activates"| MTOR["MTOR"]
        SQSTM1["SQSTM1"] -->|"activates"| MTOR["MTOR"]
        PI3K["PI3K"] -.->|"inhibits"| MTOR["MTOR"]
    end
    subgraph Interactions["Interactions"]
        MTOR["MTOR"] -->|"interacts with"| Als_3["Als"]
    end
    subgraph Pathology["Pathology"]
        MTOR["MTOR"] -->|"associated with"| Als_4["Als"]
        MTOR["MTOR"] -->|"associated with"| Mtor_5["Mtor"]
    end
    style MTOR fill:#4a1a6b,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0,font-weight:bold
    style Mtor fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Autophagy fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Als fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Autophagy_1 fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Mtor_2 fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Als_3 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Neurodegeneration fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Als_4 fill:#ef5350,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style Mtor_5 fill:#1b5e20,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style AKT fill:#006494,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style PINK1 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style LC3 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style ULK1 fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style SQSTM1 fill:#006494,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0
    style PI3K fill:#4a1a6b,stroke:#4fc3f7,stroke-width:1px,color:#e0e0e0

Outgoing (4204)

Target	Relation	Type	Str
benchmark_ot_ad_answer_key:MTOR	data_in	dataset_row	0.00
benchmark_ot_ad_answer_key:MTOR	data_in	dataset_row	0.00
Als	regulates	disease	1.00
Cancer	therapeutic_target	disease	1.00
Mtor	therapeutic_target	pathway	1.00
TP53	associated_with	gene	1.00
SQSTM1	activates	gene	1.00
Differentiation	therapeutic_target	pathway	1.00
Leukemia	therapeutic_target	disease	1.00
Inflammation	inhibits	disease	1.00
Breast Cancer	inhibits	disease	1.00
Mtor	associated_with	pathway	1.00
Mapk	activates	pathway	1.00
Aging	activates	disease	1.00
Cancer	causes	disease	1.00
Drug Resistance	therapeutic_target	pathway	1.00
Inflammation	regulates	disease	1.00
Tumor	associated_with	disease	1.00
Autophagy	associated_with	pathway	1.00
Mapk	inhibits	pathway	1.00
Infection	activates	disease	1.00
NF-KB	associated_with	protein	1.00
cancer	associated_with	disease	1.00
Pi3K/Akt	activates	pathway	1.00
PI3K	inhibits	gene	1.00
autophagy	regulates	process	1.00
PI3K	regulates	gene	1.00
P62	activates	gene	1.00
Diabetes	therapeutic_target	disease	1.00
Als	treats	disease	1.00
Neurodegeneration	associated_with	disease	1.00
PI3K	activates	gene	1.00
Nf-Κb	regulates	pathway	1.00
Tumor	inhibits	disease	1.00
Cancer	activates	disease	1.00
PARKINSON'S DISEASE	associated_with	disease	1.00
Metastasis	therapeutic_target	pathway	1.00
Breast Cancer	therapeutic_target	disease	1.00
Mtor	activates	pathway	1.00
Glycolysis	activates	pathway	1.00
Nf-Κb	inhibits	pathway	1.00
Pi3K/Akt	regulates	pathway	1.00
Glycolysis	inhibits	pathway	1.00
ds-83b31ef18d49	provides_data_for	dataset	1.00
Tumor	activates	disease	1.00
Carcinoma	therapeutic_target	disease	1.00
Pi3K/Akt	inhibits	pathway	1.00
Autophagy	regulates	pathway	1.00
Als	associated_with	disease	1.00
Cancer	inhibits	disease	1.00

Incoming (5355)

Source	Relation	Type	Str
benchmark_ot_ad_answer_key:MTOR	data_in	dataset_row	0.00
benchmark_ot_ad_answer_key:MTOR	data_in	dataset_row	0.00
GENES	inhibits	gene	1.00
MTOR	associated_with	gene	1.00
Cancer	associated_with	disease	1.00
Cancer	therapeutic_target	disease	1.00
ALZHEIMER	therapeutic_target	gene	1.00
AMPK	therapeutic_target	gene	1.00
LC3	associated_with	gene	1.00
CANCER	targets	gene	1.00
NEURODEGENERATION	associated_with	gene	1.00
AMYLOID	associated_with	gene	1.00
Aging	regulates	disease	1.00
Breast Cancer	therapeutic_target	disease	1.00
Diabetes	therapeutic_target	disease	1.00
Tumor	therapeutic_target	disease	1.00
AGING	activates	gene	1.00
AGING	activates	gene	1.00
ROS	activates	gene	1.00
GENES	associated_with	gene	1.00
Inflammation	inhibits	disease	1.00
P53	regulates	gene	1.00
INFLAMMATION	targets	gene	1.00
Leukemia	therapeutic_target	disease	1.00
SIRT1	activates	gene	1.00
MTORC1	regulates	gene	1.00
Tumor	inhibits	disease	1.00
Alzheimer	therapeutic_target	disease	1.00
Inflammation	activates	disease	1.00
CANCER	inhibits	gene	1.00
HIF	activates	gene	1.00
Aging	inhibits	disease	1.00
BECN1	activates	gene	1.00
AMPK	activates	gene	1.00
Cancer	interacts_with	disease	1.00
GENES	regulates	gene	1.00
FERROPTOSIS	therapeutic_target	gene	1.00
MITOCHONDRIAL DYSFUNCTION	activates	gene	1.00
Alzheimer	activates	disease	1.00
Neurodegeneration	activates	disease	1.00
APOPTOSIS	targets	gene	1.00
GENES	therapeutic_target	gene	1.00
GENES	activates	gene	1.00
Als	interacts_with	disease	1.00
Cancer	inhibits	disease	1.00
SIRT1	activates	gene	1.00
Cardiovascular	therapeutic_target	disease	1.00
Als	associated_with	disease	1.00
ALZHEIMER	activates	gene	1.00
FERROPTOSIS	therapeutic_target	gene	1.00

Targeting Hypotheses (22)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
APOE-Dependent Autophagy Restoration	0.895	neurodegeneration	Survival Analysis of AD Patient Cohorts:
TREM2-mTOR Co-Agonism for Metabolic Reprogramming	0.803	neurodegeneration	TREM2 agonism vs antagonism in DAM micro
TREM2-DAP12 Signalosome Enhancement — Boosting PI3K-AKT-mTOR	0.718	alzheimers	TREM2 agonism vs antagonism in DAM micro
mTORC1 Reactivation as Autophagy-Senescence Divergence Point	0.682	molecular-biology	What is the optimal therapeutic window t
mTORC1 displacement from lysosomal surface enables calcineur	0.650	neurodegeneration	What determines the specificity of calci

Microglial Metabolic Trained Immunity via mTOR-HIF1α Axis	0.644	developmental-neurobiology	Do perinatal immune challenges create pe
H7: mTOR Hyperactivity Blocks Autophagy, Permitting Tau Seed	0.640	neurodegeneration	Entorhinal cortex layer II vulnerability
mTORC1 Displacement from Lysosomal Membrane Enables TFEB Nuc	0.640	neurodegeneration	-
Caloric Restriction Mimetic Combination Therapy (Metformin +	0.640	neurodegeneration	-
Impaired TFEB/TFE3 Nuclear Translocation Due to mTORC1 Hyper	0.603	neurodegeneration	What mechanisms underlie neuronal resist
mTORC1 Hyperactivation Impairs Autophagic Flux and Drives Se	0.600	neurodegeneration	What molecular mechanisms drive microgli
REDD1-mTOR Axis as the Master Regulator — Preservation Over	0.586	neurodegeneration	Why does iron chelation therapy worsen o
Chronic mTORC1-ULK1 signaling blocks autophagy initiation in	0.578	neurodegeneration	What specific autophagy pathways are def
Synergistic enhancement of autophagy and lysosomal biogenesi	0.565	neuroscience	Lysosomal dysfunction and cathepsin leak
Autophagy Enhancement via mTOR Inhibition for C9orf72 Dipept	0.490	neurodegeneration	Test
Metabolic Checkpoint Reprogramming via TREM2-mTOR Axis	0.455	neurodegeneration	Which specific metabolic pathways in APO
CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metab	0.380	developmental-neurobiology	Do perinatal immune challenges create pe
CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metab	0.351	developmental-neurobiology	Do perinatal immune challenges create pe
mTOR Inhibition Promotes Astrocytic Clearance of Inflammator	0.000	-	Microglia-astrocyte crosstalk amplificat
Microglial Autophagy Priming Therapy	0.000	-	How do non-cell autonomous effects of au
Temporal mTOR Modulation for Sequential A1/A2 Switching	0.000	-	Astrocyte Reactivity Subtypes in Neurode
Temporal Nrf2-mTOR Dual Switch Therapy	0.000	-	Astrocyte reactivity subtypes in neurode

Mentioning Analyses (15)

Scientific analyses that reference this entity

Microglial senescence in Alzheimer and Parkinson disease progression

neurodegeneration | 2026-04-26 | 0 hypotheses

Quantitative proteomics of the aging synapse: protein turnover and aggregation i

proteomics | 2026-04-16 | 19 hypotheses Top: 0.591

Which specific metabolic pathways in APOE4+ microglia are most therapeutically t

neurodegeneration | 2026-04-08 | 7 hypotheses Top: 0.455

How do non-cell autonomous effects of autophagy dysfunction contribute to ALS pa

neurodegeneration | 2026-04-08 | 7 hypotheses Top: 0.390

Tau propagation mechanisms and therapeutic interception points

neurodegeneration | 2026-04-04 | 18 hypotheses Top: 0.814

Experiments (13)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Model	Status	Est. Cost
iPSC-NPC effects on astrocytes in vitro ICH model	exploratory	intracerebral hemorrhage	0.900	in vitro ICH cell culture mode	completed	N/A
AMPK knockdown validation experiment	exploratory	intracerebral hemorrhage	0.880	astrocyte cell culture	proposed	N/A
P2RY12-MTOR pathway interaction in VSMCs	exploratory	atherosclerosis	0.850	cultured VSMCs	proposed	N/A
iPSC-NPC transplantation in ICH animal model	validation	intracerebral hemorrhage	0.850	animal ICH model	proposed	N/A
Single-cell RNA sequencing of microglial states in AD hippocampus	exploratory	Alzheimer's disease	0.850	AD mouse hippocampus	proposed	N/A
Proximity labeling approach combined with proteomics identified subcel	computational	Alzheimer's disease	0.500	human	extracted	N/A
Proximity labeling proteomics in mouse brains revealed similar spheroi	computational	Alzheimer's disease	0.500	mouse	extracted	N/A
iPSC-derived AD model with optical electrophysiology enabled mechanist	cell_biology	Alzheimer's disease	0.500	ipsc	extracted	N/A
mTOR inhibition in mice ameliorated spheroid pathology, demonstrating	animal_model	Alzheimer's disease	0.500	in_vivo	extracted	N/A
Phosphorylated mTOR levels in spheroids correlated with AD severity in	neuropathology	Alzheimer's disease	0.500	human	extracted	N/A
Human iPSC-derived AD model with optical electrophysiology demonstrate	cell_biology	Alzheimer's disease	0.500	ipsc	extracted	N/A
mTOR inhibition in mouse AD model ameliorated spheroid pathology.	animal_model	Alzheimer's disease	0.500	in_vivo	extracted	N/A
Phosphorylated mTOR levels in axonal spheroids correlated with AD seve	neuropathology	Alzheimer's disease	0.500	in_vivo	extracted	N/A

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Replating Induces mTOR-Dependent Rescue of Protein Synthesis in Charcot-Marie-To [PMID:41876253]	Koenig J, McGuire A, Homedan Y, Alberhas	eNeuro	2026
S-equol promotes ferroptosis in triple negative breast cancer by coordinating NC [PMID:41925800]	Ni F, Huang Z, Cui Y, Huang P, Xue Z, Hu	Molecular and cellular biochem	2026
Metabolic dysregulation reshapes the immune landscape: The gut microbiota-mTOR a [PMID:41445190]	Li J, Li J, Chen K	Mol Ther	2026
Senecavirus a VP2 protein orchestrates PRDX1 degradation through dual autophagy [PMID:41479169]	Li Z, Yang X, Mao J, Zeng P, Qi Y et al.	Autophagy	2026
Inhibition of mTOR Enhances the Efficacy of Proteasome-Dependent Targeted Protei [PMID:41529091]	Liu Y, Sun Y, Song TY, Ni SY, Pu YS et a	Cancer Res	2026
Microglial metabolic reprogramming in Alzheimer's disease: Pathways, mechanisms, [PMID:41651180]	Yang FG, Yang H, Han SW, Wang JT, Gao W	Ageing Res Rev	2026
mTOR signaling pathway in primary Sjögren's syndrome: Pathogenesis and potential [PMID:41789635]	Huo R, Yang Y, Wei C, Yang Y, Meng D et	Int J Mol Med	2026
Microcystin-LR-induced phosphorylation imbalance and organelle stress: An integr [PMID:41846138]	Teng Z, Shahzad A, Xu Z, Xia J, Zhang J	J Hazard Mater	2026
Copper deficiency impairs oligodendrocyte maturation and social behavior via mit [PMID:41920999]	Usui N, Doi M, Berto S, Matsuoka K, Ishi	Sci Adv	2026
Crosstalk between inflammation and autophagy in CeD organoids. [PMID:41933042]	Bellomo C, Furone F, Auricchio R, D'Anie	Sci Rep	2026
Targeting the AKT/mTOR axis: pectolinarigenin induces autophagy and apoptosis in [PMID:41924135]	Fang Y, Bai J, Bo S, Cui X, Song H, Guo	Frontiers in pharmacology	2026
Targeting the GSK-3β/mTOR axis: a novel pharmacological strategy for preeclampsi [PMID:41922823]	Alshaikh ABA, Al-Kuraishy HM, Abdelaziz	Naunyn-Schmiedeberg's archives	2026
Platelet proteomic signatures of amyloid β-positive mild cognitive impairment an [PMID:41904574]	Cho YE, Kim A, Lee HM, Oh JW, Son SJ, Ro	Molecular brain	2026
Targeting of the PI3K/AKT/mTOR signaling pathway in the neurovascular interface [PMID:41865874]	Alameen AAM, Al-Kuraishy HM, Al-Gareeb A	Microvascular research	2026
Neuroinflammation, Autophagy, and Neurodegeneration: Mechanisms and Therapeutic [PMID:41918200]	["Khanal P", "Balmik A"]	CNS & neurological disorders d	2026
Aromatic amino acid metabolism shapes autophagy-mediated adaptation to iron depr [PMID:41925978]	Zhao K, Ludwig-Radtke L, Wang Y, Rusch T	Biometals : an international j	2026
iPSC-NPC transplantation alleviates brain injury after intracerebral hemorrhage [PMID:41921697]	Zhong Z, Wang S, Xu C, Liu Q, Chen X, Li	Journal of stroke and cerebrov	2026
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Modulating mTOR-dependent astrocyte substate transitions to alleviate neurodegen [PMID:39779911]	Zhang L, Xu Z, Jia Z, Cai S, Wu Q, Liu X	Nature aging	2025
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025

Debates (20)

Multi-agent debates referencing this entity

Extended debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.44 · 2026-04-27

Hypothesis debate: SASP Modulation Rather Than Cell Elimination

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Microglial senescence in Alzheimer and Parkinson disease progression

closed · Rounds: 6 · Score: 0.50 · 2026-04-25

Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to

closed · Rounds: 4 · Score: 0.81 · 2026-04-23

How does synaptic protein turnover change with age and neurodegeneration, and wh

closed · Rounds: 4 · Score: 0.50 · 2026-04-18

Investigate the therapeutic potential of clearing senescent cells (senolytics) t

closed · Rounds: 4 · Score: 0.75 · 2026-04-16

Investigate prion-like spreading of tau pathology through connected brain region

closed · Rounds: 4 · Score: 0.90 · 2026-04-12

Related Research

Hypotheses and analyses mentioning MTOR in their description or question text

Microglial Metabolic Trained Immunity via mTOR-HIF1α Axis

Score: 0.644 · developmental-neurobiology · 2026-04-21

**Molecular Mechanism and Rationale** The microglial metabolic trained immunity hypothesis centers on a sophisticated m

H7: mTOR Hyperactivity Blocks Autophagy, Permitting Tau Seeding

Score: 0.640 · neurodegeneration · 2026-04-22

**Molecular Mechanism and Rationale** The mechanistic target of rapamycin complex 1 (mTORC1) serves as a critical cellu

Impaired TFEB/TFE3 Nuclear Translocation Due to mTORC1 Hyperactivity in Motor Ne

Score: 0.603 · neurodegeneration · 2026-04-26

Motor neurons exhibit constitutive mTORC1 activation that phosphorylates TFEB/TFE3 transcription factors, sequestering t

mTORC1 Hyperactivation Impairs Autophagic Flux and Drives Senescence

Score: 0.600 · neurodegeneration · 2026-04-22

## Mechanistic Overview mTORC1 Hyperactivation Impairs Autophagic Flux and Drives Senescence starts from the claim that

REDD1-mTOR Axis as the Master Regulator — Preservation Over Chelation

Score: 0.586 · neurodegeneration · 2026-04-15

## Mechanistic Overview REDD1-mTOR Axis as the Master Regulator — Preservation Over Chelation starts from the claim that

Chronic mTORC1-ULK1 signaling blocks autophagy initiation in irradiated pericyte

Score: 0.578 · neurodegeneration · 2026-04-25

DNA damage and SASP signaling keep initiation suppressed, producing a durable upstream autophagy defect.

Synergistic enhancement of autophagy and lysosomal biogenesis by combined mTOR i

Score: 0.565 · neuroscience · 2026-04-22

## Mechanistic Overview Synergistic enhancement of autophagy and lysosomal biogenesis by combined mTOR inhibition and TF

Autophagy Enhancement via mTOR Inhibition for C9orf72 Dipeptide Repeat Pathology

Score: 0.490 · neurodegeneration · 2026-04-28

C9orf72 repeat expansions produce toxic dipeptide repeats (DPRs) that impair nucleocytoplasmic transport and autophagy.

Metabolic Checkpoint Reprogramming via TREM2-mTOR Axis

Score: 0.455 · neurodegeneration · 2026-04-27

Restore oxidative metabolism in APOE4 microglia through CNS-penetrant mTOR modulators that reactivate oxidative phosphor

CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metabolic Reprogramming i

Score: 0.380 · developmental-neurobiology · 2026-04-27

This hypothesis proposes that perinatal immune activation triggers CCR2-dependent recruitment of bone marrow-derived mon

CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metabolic Reprogramming i

Score: 0.351 · developmental-neurobiology · 2026-04-26

This hypothesis proposes that perinatal immune activation triggers a two-phase pathogenic cascade where CCR2-mediated re

mTOR Inhibition Promotes Astrocytic Clearance of Inflammatory Proteins

Score: 0.000 · unknown disease · 2026-04-28

Enhancing autophagy specifically in reactive astrocytes through targeted mTOR inhibition could accelerate clearance of a

Microglial Autophagy Priming Therapy

Score: 0.000 · unknown disease · 2026-04-28

Selectively enhancing autophagy in microglia using cell-type-specific delivery systems to reduce SOD1 processing impairm

MTOR

Understanding Entity Pages

Summary

Wiki Pages (10)

Combination Logic Ideas — Cross-Modality Pairings

MTOR Gene

RPTOR — Regulatory Associated Protein of MTOR Complex 1

LAMTOR2 Gene

MTOR Gene

MTOR Protein

LAMTOR2 Protein

LAMTOR1 - Late Endosomal/Lysosomal Adaptor 1

MTOR Protein

MTOR (Redirect)

Pathway Diagram

Outgoing (4204)

Incoming (5355)

Targeting Hypotheses (22)

Mentioning Analyses (15)

Microglial senescence in Alzheimer and Parkinson disease progression

Quantitative proteomics of the aging synapse: protein turnover and aggregation i

Which specific metabolic pathways in APOE4+ microglia are most therapeutically t

How do non-cell autonomous effects of autophagy dysfunction contribute to ALS pa

Tau propagation mechanisms and therapeutic interception points

Senescent cell clearance as neurodegeneration therapy

Does TFEB dysfunction cause neurodegeneration or represent a compensatory respon

Gene expression changes in aging mouse brain predicting neurodegenerative vulner

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas

Senescent cell clearance as neurodegeneration therapy

TREM2 agonism vs antagonism in DAM microglia

Sleep disruption as cause and consequence of neurodegeneration

Astrocyte Reactivity Subtypes in Neurodegeneration

Mechanistic role of APOE in neurodegeneration

Mechanistic role of APOE in neurodegeneration

Experiments (13)

Related Papers (20)

Debates (20)

Extended debate: Metabolic Reprogramming to Reverse Senescence

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

Hypothesis debate: SASP Modulation Rather Than Cell Elimination

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

Microglial senescence in Alzheimer and Parkinson disease progression

Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to

How does synaptic protein turnover change with age and neurodegeneration, and wh

Investigate the therapeutic potential of clearing senescent cells (senolytics) t

Investigate prion-like spreading of tau pathology through connected brain region

Related Research

Microglial Metabolic Trained Immunity via mTOR-HIF1α Axis

H7: mTOR Hyperactivity Blocks Autophagy, Permitting Tau Seeding

Impaired TFEB/TFE3 Nuclear Translocation Due to mTORC1 Hyperactivity in Motor Ne

mTORC1 Hyperactivation Impairs Autophagic Flux and Drives Senescence

REDD1-mTOR Axis as the Master Regulator — Preservation Over Chelation

Chronic mTORC1-ULK1 signaling blocks autophagy initiation in irradiated pericyte

Synergistic enhancement of autophagy and lysosomal biogenesis by combined mTOR i

Autophagy Enhancement via mTOR Inhibition for C9orf72 Dipeptide Repeat Pathology

Metabolic Checkpoint Reprogramming via TREM2-mTOR Axis

CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metabolic Reprogramming i

CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metabolic Reprogramming i

mTOR Inhibition Promotes Astrocytic Clearance of Inflammatory Proteins

Microglial Autophagy Priming Therapy